Tuesday, April 30, 2024
Home Biotech News Glutathione Page 2

Glutathione

    Random

    Revive Therapeutics (RVVTF) Enters the Danger Zone.

    Glutathione Editor / Curator -
    What Danger You Ask? Danger #1, the FDA doesn't like the data, and you own the stock.

    Revive Therapeutics (RVVTF) Regulatory Update Archive.

    Biotech News Editor / Curator -
    April 12th, 2022 update. Discusses potentially halting the Study early due to positive efficacy based on other clinical outcomes evaluated such as...
    Dr John Fahy UCSF

    Revive Therapeutics (RVVTF) Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

    Glutathione Editor / Curator -
    TORONTO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life...
    12Page 2 of 2

    Latest article

    Adding Citius Pharma (CTXR) $0.66 to 2024 Watch List.

    2024 Watch List Editor / Curator -
    Three Years Since we Last Added Citius (CTXR) to the Watch List, and it Looks Better Than Ever!

    Citius Pharmaceuticals (CTXR) Prospectus, Powerpoint & Fact Sheet.

    2024 Watch List Editor / Curator -
    CRANFORD, N.J., April 26, 2024 /PRNewswire/ -- Citius Pharmaceuticals Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a late-stage biopharmaceutical company dedicated to the development and commercialization...

    GeoVax (GOVX) Launches Vaccine Manufacturing System.

    2024 Watch List Editor / Curator -
    GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System Manufacturing Process for Phase 3 and Commercial Production...
    The Internet Stock Review is one of Wall Streets oldest newsletters covering internet technology having launched in 1999. The Biotech Stock Review is rather old too, having launched in 2002. We make our money by purchasing stock with our services, so the better our client stocks do, the better we all do. And when we're wrong, we feel the pain too! See our research reports for important disclaimer details. Content is provided by Institutional Analyst Inc., the website is managed by Revelers.IO Media Group Inc. To see if your Company qualifies for coverage, call 310-594-8062
    Contact us: [email protected]
    © Managed by Revelers.IO Media Group Inc.